Santhera Pharmaceuticals Return On Equity vs. EBITDA
| SANN Stock | CHF 8.20 0.07 0.85% |
For Santhera Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Santhera Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Santhera Pharmaceuticals Holding utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Santhera Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Santhera Pharmaceuticals Holding over time as well as its relative position and ranking within its peers.
Santhera |
Santhera Pharmaceuticals EBITDA vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Santhera Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Santhera Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Santhera Pharmaceuticals Holding is rated fourth in return on equity category among its peers. It also is rated fourth in ebitda category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Santhera Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Santhera EBITDA vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Santhera Pharmaceuticals |
| = | -13.16 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Santhera Pharmaceuticals |
| = | (34.57 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Santhera EBITDA Comparison
Santhera Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Santhera Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Santhera Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Santhera Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Santhera Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Santhera Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland. SANTHERA N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 114 people.
Santhera Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Santhera Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Santhera Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Santhera Pharmaceuticals' important profitability drivers and their relationship over time.
Use Santhera Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Santhera Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Santhera Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Santhera Pharmaceuticals Pair Trading
Santhera Pharmaceuticals Holding Pair Trading Analysis
The ability to find closely correlated positions to Santhera Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Santhera Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Santhera Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Santhera Pharmaceuticals Holding to buy it.
The correlation of Santhera Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Santhera Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Santhera Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Santhera Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Santhera Pharmaceuticals position
In addition to having Santhera Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Munis Funds Thematic Idea Now
Munis Funds
Funds or Etfs that invest in fixed income securities issued by states, cities, and towns as well as other public entities. The Munis Funds theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Munis Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.